Brett Staahl
CIK: 0002147277
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Scribe Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19.4K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectPerformance-based Stock Option (Right to Buy)
19.4K shares- - Mar 13, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
4.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,385 | - | - | Direct |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Performance-based Stock Option (Right to Buy) | 19,385 | - | - | Direct |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 4,755 | - | - | Direct |
1-3 of 3 transactions
About Staahl Brett
Staahl Brett (SEC CIK 0002147277) files insider reports with the SEC as 10% Owner of Scribe Therapeutics, Inc. (SCTX).
Signal8 holds 2 ownership filings by Staahl Brett (1 Form 3, 1 Form 4), filed between Jul 23, 2026 and Jul 28, 2026. Those filings report 3 transactions, from Mar 13, 2026 to Jul 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Staahl Brett's filings is in ALAMEDA, CA.
Recent filings by Staahl Brett
Other insiders filing for Scribe Therapeutics, Inc. (SCTX)
- AH Bio Fund II, L.P., 10% Owner
- GORDON CARL L, Director
- ORBIMED ADVISORS LLC, Director
- Doudna Jennifer A, 10% Owner
- Aghazadeh Behzad, Director
- Lucas Svetlana, Chief Business Officer